Display options
Cite
Alreshq R, Tugal D, Siddiqi O, et al. Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis: A systematic review. Pacing Clin Electrophysiol. 2021;44(12):2092-2099doi: 10.1111/pace.14375.
Alreshq, R., Tugal, D., Siddiqi, O., & Ruberg, F. (2021). Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis: A systematic review. Pacing and clinical electrophysiology : PACE, 44(12), 2092-2099. https://doi.org/10.1111/pace.14375
Alreshq, Rabah, et al. "Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis: A systematic review." Pacing and clinical electrophysiology : PACE vol. 44,12 (2021): 2092-2099. doi: https://doi.org/10.1111/pace.14375
Alreshq R, Tugal D, Siddiqi O, Ruberg F. Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis: A systematic review. Pacing Clin Electrophysiol. 2021 Dec;44(12):2092-2099. doi: 10.1111/pace.14375. Epub 2021 Oct 24. PMID: 34632598.
Copy Download .nbib Format: NLM
Share it on

Pacing Clin Electrophysiol. 2021 Dec;44(12):2092-2099. doi: 10.1111/pace.14375. Epub 2021 Oct 24.

Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis: A systematic review.

Pacing and clinical electrophysiology : PACE

Rabah Alreshq, Derin Tugal, Omar Siddiqi, Frederick Ruberg

Affiliations

  1. Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
  2. Amyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
  3. Department of Radiology, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts, USA.

PMID: 34632598 DOI: 10.1111/pace.14375

Abstract

Cardiac amyloidosis (CA) is an increasingly recognized cause of heart failure, characterized by extracellular deposition of insoluble protein fibrils leading to progressive myocardial dysfunction. The most common types of cardiac amyloidosis are immunoglobin light-chain (AL) and transthyretin (ATTR). Conduction abnormalities are commonly encountered among patients with cardiac amyloidosis and are an important cause of morbidity and mortality. Abnormalities range from infra-Hisian intraventricular conduction delay and bundle branch block to complete atrioventricular block. Pacemaker placement in CA patients follows established guidelines, similar to those for patients without CA, with generally good efficacy. The role and appropriate timing of pacemakers for primary prevention of brady-arrhythmias in CA remains uncertain. While biventricular (BiV) pacing has been shown to improve clinical outcomes in patients with systolic heart failure without CA, there are few data examining the utility of BiV pacing in patients with CA. With the advent of effective treatments for AL and ATTR, appropriate application of pacing is important to support patients with CA and conduction disease through therapeutic trials. This systematic review summarizes the current literature examining the utility of pacing in CA.

© 2021 Wiley Periodicals LLC.

Keywords: bradyarrhythmias; cardiac amyloidosis; cardiac pacing; conduction disease; pacemakers

References

  1. Griffin JM, Maurer MS. Cardiac Amyloidosis a rare disease in older adults hospitalized for heart failure?. Circ Heart Fail. 2019;12:e006169. - PubMed
  2. Falk RH, Alexander KM, Liao R, et al. AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68:1323-1341. - PubMed
  3. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451-2466. - PubMed
  4. Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: jACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2872-2891. - PubMed
  5. Cavalcante JL, Rijal S, Abdelkarim I, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson. 2017;19:98. - PubMed
  6. Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879-2887. - PubMed
  7. Martinez-Naharro A, Baksi AJ, Hawkins PN, et al. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol. 2020;17:413-426. - PubMed
  8. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142:e7-e22. - PubMed
  9. Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:38. - PubMed
  10. Frustaci A, Letizia C, Adamo F, et al. A-V block as presentation of cardiac amyloid: prominent infiltration of conduction tissue revealed by endomyocardial biopsy. Amyloid. 2017;24:131-132. - PubMed
  11. Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med. 1977;62:677-686. - PubMed
  12. Dorbala S, Vangala D, Bruyere J, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2:358-367. - PubMed
  13. Eriksson P, Karp K, Bjerle P, et al. Disturbances of cardiac rhythm and conduction in familial amyloidosis with polyneuropathy. Br Heart J. 1984;51:658-662. - PubMed
  14. Donnellan E, Wazni OM, Saliba WI, et al. Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis. Am J Cardiol. 2020;128:140-146. - PubMed
  15. Algalarrondo V, Dinanian S, Juin C, et al. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm. 2012;9:1069-1075. - PubMed
  16. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11-21. - PubMed
  17. Barbhaiya CR, Kumar S, Baldinger SH, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016;13:383-390. - PubMed
  18. Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiologic abnormalities in AL (Primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30:1046-1051. - PubMed
  19. Narula OS, Scherlag BJ, Samet P, et al. Atrioventricular block. Localization and classification by His bundle recordings. Am J Med. 1971;50:146-165. - PubMed
  20. Boldrini M, Salinaro F, Mussinelli R, et al. Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013;18:327-335. - PubMed
  21. Towbin JA, McKenna WJ, Abrams DJ, et al. HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019;16:e301-e372. - PubMed
  22. Eriksson P, Olofsson BO. Pacemaker treatment in familial amyloidosis with polyneuropathy. Pacing Clin Electrophysiol. 1984;7:702-706. - PubMed
  23. Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J. 2015;36:1098-1105. - PubMed
  24. Falk RH, Rubinow A, Cohen AS. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol. 1984;3:107-113. - PubMed
  25. Givens RC, Russo C, Green P, et al. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health. 2013;9:229-235. - PubMed
  26. Milner J, Teixeira RN, Marinho AV, et al. Pacemaker implantation in familial amyloid polyneuropathy: when and for whom?. J Interv Card Electrophysiol. 2019;55:207-211. - PubMed
  27. Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2:e000098. - PubMed
  28. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61:e6-75. - PubMed
  29. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140:e382-e482. - PubMed
  30. Donnellan E, Wazni OM, Saliba WI, et al. Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol. 2019;30:2427-2432. - PubMed
  31. Lopez-Sainz A, de Haro-Del Moral FJ, Dominguez F, et al. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders. Amyloid. 2019;26:156-163. - PubMed
  32. Mathew V, Olson LJ, Gertz MA, et al. Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol. 1997;80:1491-1492. - PubMed
  33. Rehorn MR, Loungani RS, Black-Maier E, et al. Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis. JACC Clin Electrophysiol. 2020;6:1144-1154. - PubMed
  34. Mathew V, Chaliki H, Nishimura RA. Atrioventricular sequential pacing in cardiac amyloidosis: an acute Doppler echocardiographic and catheterization hemodynamic study. Clin Cardiol. 1997;20:723-725. - PubMed

Publication Types

Grant support